Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/28/2022 -- Results Q3 2022 -- 1.36 --
10/28/2022 -- Earnings Call Q3 2022 -- -- --
07/28/2022 -- Results Q2 2022 0.88 0.87 0.66%
07/28/2022 -- Earnings Call Q2 2022 -- -- --
04/28/2022 -- Results Q1 2022 1.02 0.92 11.26%
04/28/2022 -- Earnings Call Q1 2022 -- -- --
02/04/2022 -- Results Q4 2021 0.79 0.72 9.42%
02/04/2022 -- Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/28/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/28/2022
Beat/Miss Upgrade
Return Since -13.92%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
URL https://www.sanofi.com
Investor Relations URL https://www.sanofi.com/en/investors
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Oct. 28, 2022
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 26, 2022

Dividends

Dividend Per Share (TTM) 1.765
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 3.217
Yield to Sector 2.437
Yield to Industry 1.152
Last Dividend Amt. 0.2972
Dividend Frequency Annually
Last Ex-Dividend Date May. 26, 2022
Yield (TTM) 3.90%
Forward Yield 3.90%
Payout Ratio 58.96%
Cash Payout Ratio 22.82%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-3.45%
-1.15%
9.94%
5.95%
20.53%
0.31%
7.02%
-9.12%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.98%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
20.24%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
1.86%
39.32%
-36.56%
54.26%
-11.88%
28.69%
23.31%
63.39%
-4.12%
0.86%
3.28%
-1.81%
15.13%
30.64%
-16.73%
28.38%
-20.50%
As of August 15, 2022.

Profile

Edit
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
URL https://www.sanofi.com
Investor Relations URL https://www.sanofi.com/en/investors
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Oct. 28, 2022
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 26, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
FPHAX 74.97M USD 9.27%
LIFE.TO 11.48M USD 4.84%
PPH 24.60M USD 4.23%
HIG.TO 2.837M USD 4.14%
DOXGX 2.701B USD 3.16%
BDIV.TO 1.888M USD 2.26%
FETKX 120.58M USD 2.19%
PID 17.75M USD 2.17%
JDVPX 235.59M USD 2.06%
DOXBX 279.98M USD 2.03%
CII 17.10M USD 1.83%
ACSYX 141.84M USD 1.55%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter SNY Tweets